Evidence map›Paper›PMID 33628745›Full record

ReviewFrontiers in cellular and infection microbiology2020

The Macrophage Response to

Retsepile E Maphasa, Mervin Meyer, Admire Dube

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Drug resistance mechanisms inFrontiers in pharmacology · 2026
    Review
  13. Host-pathogen-immune interactions in an air-liquid interface airway model.Frontiers in cellular and infection microbiology · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Retsepile E MaphasaInfectious Disease Nanomedicine Research Group, School of Pharmacy, University of the Western Cape, Cape Town, South Africa.
Mervin MeyerDST/Mintek Nanotechnology Innovation Centre, Biolabels Node, Department of Biotechnology, University of the Western Cape, Cape Town, South Africa.
Admire DubeInfectious Disease Nanomedicine Research Group, School of Pharmacy, University of the Western Cape, Cape Town, South Africa.
University of the Western Cape · ZA

Funding

Development of Nanomedicines for Tuberculosis TreatmentK43TW010371 · FIC · UNIVERSITY OF THE WESTERN CAPE · PI DUBE, ADMIRE · 2017 to 2021
$370k
FIC NIH HHS K43 TW010371
6 · The paper itself

Abstract

The major causative agent of tuberculosis (TB), i.e.,

Indexed as

Mycobacterium tuberculosisTuberculosisAutophagyHumansMacrophagesNanomedicineapoptosis and tuberculosisautophagy and tuberculosishost directed therapiesimmunotherapeutic nanoparticlesinnate immunityLC3-associated phagocytosisMycobacterium tuberculosisxenophagy

Identifiers

PMID33628745
PMCPMC7897680
OpenAlexW3126708712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.